Company achieved profitability in Q4 2025, secured $20.2 million PIPE financing with potential additional $20.2 million, made progress on registrational PCNSL trial on track for 12-18 month enrollment timeline, initiated CLL proof-of-concept study with initial data expected at ASH December 2026, and demonstrated encouraging early AML triplet therapy results (5 of 8 patients achieved MRD conversion). Management is strategically focused on NHL programs with clear resource prioritization.
Also mentions CRIS
Articles that tag CRIS but are mainly about other companies.
Mentioned only as a previous employer of the newly appointed CEO. No direct business impact or news regarding Curis is discussed in the article.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
